Common Stock, $0.0001 par value per share
- Symbol
- IXHL
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 7.01, 9.01 · 8-K
Incannex Healthcare Inc.
IXHLNASDAQEQUITYCurrent
Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On August 11, 2026, Incannex Healthcare Inc. (the “Company”) issued the press release furnished as Exhibit 99.1. The information contained in Item 7.01 in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “…
Company context
Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company developing innovative combination therapies and next-generation medicines for conditions with significant unmet medical need. The Company’s lead programs include IHL-42X for obstructive sleep apnea and PSX-001 for generalized anxiety disorder. Incannex is committed to advancing therapies that address multiple biological pathways with the goal of improving patient outcomes and creating long-term shareholder value. For more information, please visit www.incannex.com.
Current securities
Historical securities (1)
Registered securities in this filing
Incannex Healthcare Inc. · 8-K · Filed 2026-08-11
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
Item
7.01 Regulation FD Disclosure.
On August
11, 2026, Incannex Healthcare Inc. (the “Company”) issued the press release furnished as Exhibit 99.1.
The information
contained in Item 7.01 in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be
deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities
Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Filed exhibits (1)
EX-99.1 2 ea030133301ex99-1.htm PRESS RELEASE DATED AS OF AUGUST 11, 2026 Exhibit 99.1 Incannex Receives Additional A$5.1 Million R&D Tax Incentive Refund, Completing More Than A$11.2 Million in Non-Dilutive Capital Received in 2026 Completion of more than A$11.2 million in non-dilutive capital received under the Australian Government’s R&D Tax Incentive Program further strengthens Company’s balance sheet and financial flexibility NEW YORK and MELBOURNE, Australia, Tuesday, 11 August, 2026 - Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative combination therapies and psychedelic-assisted treatments, today announced it has received the final A$5,102,788.30 refund under the Australian Government’s Research and Development Tax Incentive Program following approval of the Company’s overseas findings and amendment of its FY25 income tax return. Together with the previously announced A$6,039,162.43 refund, Incannex has now received more than A$11.2 million in non-dilutive capital during 2026. The receipt further enhances Incannex’s already strong cash position and debt-free balance sheet, providing…
Open exhibit ↗